AzTrials
AzTrials

Rheumatoid ArthritisPhase 2NCT00887341

A Study Comparing Infusion Rates of Tocilizumab in Patients With Moderate to Severe Rheumatoid Arthritis

A Phase 2 study testing tocilizumab [RoActemra/Actemra] in people with Rheumatoid Arthritis, run by Hoffmann-La Roche at 24 sites in Spain.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This 2 arm study will compare the incidence of tocilizumab-related infusion reactions, using 2 different infusion times, in patients with moderate to severe rheumatoid arthritis who have shown an inadequate response to DMARDs (Disease Modifying Anti Rheumatic Drugs) or anti-TNFs.Patients will be randomized to one of 2… Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Rheumatoid Arthritis
What is being tested?
tocilizumab [RoActemra/Actemra]
Type of treatment
Injection or infusion
Could I receive a placebo?
No, everyone receives an active treatment
How many people
76 participants
Where
24 sitesSpain
Study dates
May 2009to Dec 2010
Phase
Phase 2
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • adult patients, >=18 years of age;
  • active moderate or severe rheumatoid arthritis;
  • active disease for >6 months;
  • inadequate response to a stable dose of non-biologic DMARDs or antiTNFs.

Who cannot join

  • rheumatic autoimmune disease other than rheumatoid arthritis;
  • prior history of, or current inflammatory joint disease other than rheumatoid arthritis;
  • major surgery (including joint surgery) within 8 weeks prior to screening, or planned major surgery within 6 months following enrollment.

Trial locations and contacts

24 sites in 1 country.

24 sites in 1 country

Spain24 sites
  • Study site

    Alcalá de Henares, Madrid, 28805

  • Study site

    Alzira, Valencia, 46600

  • Study site

    Ávila, Avila, 05071

  • Study site

    Badalona, Barcelona, 08915

  • Study site

    Castellon, Castellon, 12004

  • Study site

    Galdakao, Vizcaya, 48960

  • Study site

    Gijón, Principality of Asturias, 33394

  • Study site

    L'Hospitalet de Llobregat, Barcelona, 08906

  • Study site

    Madrid, Madrid, 28031

  • Study site

    Madrid, Madrid, 28935

  • Study site

    Menorca, Balearic Islands, 07701

  • Study site

    Mollet del Vallès, Barcelona, 08100

  • Study site

    Oviedo, Principality of Asturias, 33006

  • Study site

    Palma de Mallorca, Balearic Islands, 07014

  • Study site

    Palma de Mallorca, Balearic Islands, 07198

  • Study site

    San Juan, Valencia, 03550

  • Study site

    San Sebastián de los Reyes, Madrid, 28702

  • Study site

    Torrelavega, Cantabria, 39300

  • Study site

    Valenica, Valencia, 46009

  • Study site

    Vigo, Pontevedra, 36204

  • Study site

    Vigo, Pontevedra, 36214

  • Study site

    Villajoyosa, Alicante, 03570

  • Study site

    Vitoria-Gasteiz, Alava, 01009

  • Study site

    Zaragoza, Zaragoza, 50009

Other trials in Spain

About this study

Official title: Phase II Multi-centre, Randomized, Parallel Group, Pilot Trial to Compare the Incidence of Tocilizumab Related Infusion Reactions in Moderate to Severe RA Patients When Infusion is Made Over 1 Hour Against 31 Minutes

This 2 arm study will compare the incidence of tocilizumab-related infusion reactions, using 2 different infusion times, in patients with moderate to severe rheumatoid arthritis who have shown an inadequate response to DMARDs (Disease Modifying Anti Rheumatic Drugs) or anti-TNFs.Patients will be randomized to one of 2 groups, to receive tocilizumab 8mg/kg iv every 4 weeks either a)over a 1h infusion time for all administrations or b) a 1h infusion time for the first administration, followed by a 31 minute infusion time for subsequent administrations (unless drug-related infusion reactions occur).The anticipated time on study treatment is 3-12 months, and the target sample size is <100 individuals.

Being tested
tocilizumab [RoActemra/Actemra]
Medical subject headings
Arthritis, Rheumatoid

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • tocilizumab [RoActemra/Actemra]Drug

    8mg/kg iv every 4 weeks for 6 infusions; first infusion 1h duration, subsequent infusions 31 minutes duration

  • tocilizumab [RoActemra/Actemra]Drug

    8mg/kg iv every 4 weeks for 6 infusions; each infusion 1h duration

Study groups in NCT00887341
Study groupRoleWhat they receive
1ExperimentalNot described
Receives: Drug: tocilizumab [RoActemra/Actemra]
2Active comparatorNot described
Receives: Drug: tocilizumab [RoActemra/Actemra]

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Percentage of Participants With an Infusion Reaction Within 24 Hours After Infusion

    An infusion reaction was defined as any adverse event (AE) that occurred during the infusion or during the 24 hours following the infusion.

    Measured: Screening, Baseline, and Weeks 4, 8, 12, 16, 20, and 24

Secondary outcomes (14)
  1. Percentage of Participants Discontinuing Tocilizumab in Response to an AE or Serious AE (SAE)

    Measured: Weeks 4, 8, 12, 16, 20 and Final Visit

  2. Percentage of Participants Discontinuing Tocilizumab for Any Reason

    Measured: Weeks 4, 8, 12, 16, 20 and Final Visit

  3. Percentage of Participants With a Reduction of at Least 1.2 Units on the Disease Activity Scale Based on 28-Joint Count (DAS28) by Visit

    DAS28 calculated from the number of swollen joints and tender joints using the 28-joint count, the erythrocyte sedimentation rate (ESR) (millimeters per hour [mm/hr]) and Patient's Global Assessment of Disease (participant-rated arthritis activity assessment) with transformed scores ranging 0 to 10; higher scores indicated greater affectation due to disease activity. DAS28 less than or equal to (≤)3.2 equals (=) low disease activity, DAS28 greater than (>)3.2 to 5.1 = moderate to high disease activity; DAS28 less than (<) 2.6 = remission. A reduction of at least 1.2 units was considered a clinically significant difference.

    Measured: Weeks 4, 8, 12, 16, 20 and Final Visit

  4. Percentage of Participants Achieving a DAS28 Score <3.2 by Visit

    DAS28 calculated from the number of swollen joints and tender joints using the 28-joint count, the ESR (mm/hr), and Patient's Global Assessment of Disease (participant-rated arthritis activity assessment) with transformed scores ranging 0 to 10; higher scores indicated greater affectation due to disease activity. DAS28 ≤3.2=low disease activity, DAS28 >3.2 to 5.1=moderate to high disease activity; DAS28 <2.6=remission.

    Measured: Weeks 4, 8, 12, 16, 20 and Final Visit

  5. Percentage of Participants Achieving a DAS28 Score <2.6 (Remission)

    DAS28 calculated from the number of swollen joints and tender joints using the 28-joint count, the ESR (mm/hr) and Patient's Global Assessment of Disease (participant-rated arthritis activity assessment) with transformed scores ranging 0 to 10; higher scores indicated greater affectation due to disease activity. DAS28 ≤3.2=low disease activity, DAS28 >3.2 to 5.1=moderate to high disease activity; DAS28 <2.6=remission.

    Measured: Weeks 4, 8, 12, 16, 20 and Final Visit

  6. DAS28 Score by Visit

    DAS28 calculated from the number of swollen joints and tender joints using the 28-joint count, the ESR (mm/hr) and Patient's Global Assessment of Disease (participant-rated arthritis activity assessment) with transformed scores ranging 0 to 10; higher scores indicated greater affectation due to disease activity. DAS28 ≤3.2=low disease activity, DAS28 >3.2 to 5.1=moderate to high disease activity; DAS28 <2.6=remission. Last observation carried forward (LOCF) visit took the last non-missing post-baseline available value.

    Measured: Weeks 4, 8, 12, 16, 20, and Final Visit

  7. Percentage of Participants Achieving American College of Rheumatology 20 Percent (%) Improvement (ACR20 Response)

    ACR20 response defined as an improvement of ≥20% in swollen joint count (SJC; 66 joints) and tender joint count (TJC; 68 joints) as well as ≥20% improvement in at least 3 of the following 5 remaining ACR assessments: Patient Global Assessment of Pain; Patient Global Assessment of Disease Activity; Physician Global Assessment of Disease Activity; Health Assessment Questionnaire - Disability Index (HAQ-DI); and acute phase reactive factors (ESR or C-Reactive Protein [CRP])

    Measured: Weeks 4, 8, 12, 16, 20 and Final Visit

  8. Percentage of Participants Achieving ACR 50% Improvement (ACR50 Response)

    ACR50 response defined as an improvement of ≥50% in SJC (66 joints) and TJC (68 joints) as well as ≥50% improvement in at least 3 of the following 5 remaining ACR assessments: Patient Global Assessment of Pain; Patient Global Assessment of Disease Activity; Physician Global Assessment of Disease Activity; HAQ-DI; and acute phase reactive factors (ESR or CRP).

    Measured: Weeks 4, 8, 12, 16, 20 and Final Visit

  9. Percentage of Participants Achieving ACR 70% Improvement (ACR70 Response)

    ACR70 response defined as an improvement of ≥70% in SJC (66 joints) and TJC (68 joints) as well as ≥70% improvement in at least 3 of the following 5 remaining ACR assessments: Patient Global Assessment of Pain; Patient Global Assessment of Disease Activity; Physician Global Assessment of Disease Activity; HAQ-DI; and acute phase reactive factors (ESR or CRP).

    Measured: Weeks 4, 8, 12, 16, 20 and Final Visit

  10. Percentage of Participants Achieving ACR 90% Improvement (ACR90 Response)

    ACR90 response defined as an improvement of ≥90% in SJC (66 joints) and TJC (68 joints) as well as ≥90% improvement in at least 3 of the following 5 remaining ACR assessments: Patient Global Assessment of Pain; Patient Global Assessment of Disease Activity; Physician Global Assessment of Disease Activity; HAQ-DI; and acute phase reactive factors (ESR or CRP).

    Measured: Weeks 4, 8, 12, 16, 20 and Final Visit

  11. C-Reactive Protein (CRP) Levels

    CRP is an inflammation marker. High levels of this protein indicate inflammation in diseases such as Rheumatoid Arthritis. CRP is measured in milligrams per liter (mg/L).

    Measured: Screening, Baseline, Weeks 4, 8, 12, 16, 20, and Final Visit

  12. Erythrocyte Sedimentation Rate

    ESR is an acute phase reactant measured in mm/hr. Reduction in ESR indicates improvement.

    Measured: Baseline, Weeks 2, 4, 8, 12,16, 20, and 24

  13. HAQ-DI Score by Visit

    HAQ-DI is a self-reported, valid assessment of functional disability in rheumatoid arthritis. Assessment based on ability of participants to perform daily activities in 8 categories: dressing, arising, eating, walking, reaching, gripping, hygiene, and carrying out daily activities. HAQ-DI scores range: 0-3: without any difficulty=0, with some difficulty=1, with much difficulty=2, unable to do=3. HAQ-DI total scores expressed as overall mean score with range 0-3: 0-0.25=normal functioning; 0.25-0.5=mild functional limitation; 0.5-1=moderate functional limitation; more than 1=significant functional limitation.

    Measured: Baseline, Weeks 2, 4, 8, 12, 16, 20 and 24

  14. Percentage of Participants With Improvement of at Least 0.22 in HAQ-DI

    HAQ-DI is a self-reported, valid assessment of functional disability in rheumatoid arthritis. Assessment based on ability of participants to perform daily activities in 8 categories: dressing, arising, eating, walking, reaching, gripping, hygiene, and carrying out daily activities. HAQ-DI scores range: 0-3: without any difficulty=0, with some difficulty=1, with much difficulty=2, unable to do=3. HAQ-DI total scores expressed as overall mean score with range 0-3: 0-0.25=normal functioning; 0.25-0.5=mild functional limitation; 0.5-1=moderate functional limitation; more than 1=significant functional limitation. An improvement of 0.22 units in HAQ-DI was considered to be a clinically significant improvement.

    Measured: Weeks 4, 8, 12, 16, 20 and Final Visit

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted23 Apr 2009 (estimated)
  2. Study startMay 2009
  3. Primary completionDec 2010
  4. Study completionDec 2010

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
76 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT00887341
Sponsor's protocol ID
ML22254
Other IDs
2008-006443-39, 2008
Status last verified
Oct 2014
First submitted
22 Apr 2009
Last updated
22 Oct 2014

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing tocilizumab [RoActemra/Actemra] in people with Rheumatoid Arthritis, run by Hoffmann-La Roche at 24 sites in Spain.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 22 Oct 2014. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 24 sites in Spain. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 22 Oct 2014). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Percentage of Participants With an Infusion Reaction Within 24 Hours After Infusion (time frame: Screening, Baseline, and Weeks 4, 8, 12, 16, 20, and 24). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Oct 2014.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in